Anti-Mouse/Human TGF-β1, 2, 3 – Purified in vivo PLATINUM™ Functional Grade
Pricing & Details
Bovine TGFβ isoform 2
≥ 5.0 mg/ml
<0.5 EU/mg as determined by the LAL method
≥98% monomer by analytical SEC
>95% by SDS Page
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Next Day 2-8°C
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Mouse Anti-Human/Mouse Transforming Growth Factor-Beta 1, 2, 3 (TGF-β1,2,3) (Clone 1D11) recognizes an epitope on Human/Mouse TGF-β1,2,3. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Heterodimeric receptor consisting of type I (TbRI) and type II (TbRII).
References & Citations
1. Guven, M. et al. (2007) Growth Factors 25: 101
2. Schneider, J. et al. (2009) J Investing Med. 57(5):655-61
3. Yu, C. et al. (2009) Biochem Biophys Res Commun. 406(2):204-210